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Introduction
Hepatitis B virus (HBV) infection is a major public health problem and a leading cause of morbidity and mortality globally, affecting approximately 250 million persons worldwide [1] and accounting for 650,000 deaths annually [2] . Most of these deaths occur in resource-limited countries in Asia and Africa. Without effective preventive and therapeutic interventions chronic hepatitis B (CHB) infection will lead to an estimated 11.8 million deaths by 2030, primarily as a result of cirrhosis and hepatocellular carcinoma (HCC) [3] . The World Health Organization (WHO) has recently incorporated HBV elimination in its global health agenda and plans a 90% reduction of anew HBV cases and a 65% reduction of HBVrelated mortality by 2030. In order to achieve these ambitious targets prevention of HBV transmission in particularly in endemic countries should be urgently improved. Effective HBV vaccines have been developed in the early 80s and in 2009, the WHO has recommended the introduction of the vaccine into the national immunization programs of all endemic countries. However, the current coverage of three doses of HBV vaccines remains imperfect with an estimate below 80% in 2015 in Africa [4] . In sub-Saharan Africa, the seroprevalence of Hepatitis B s antigen (HBsAg) in the adult population is high, estimated over 8% [1, 5] . In Senegal, 85% of the population has at least one marker of previous or current HBV infection and the prevalence of HBsAg varies between 11 to 17% [6] .
Following three doses of vaccine given at 4 weeks interval, it has been demonstrated that 90-99% of healthy neonates, children, adolescents and adults will develop protective levels of HBs antibody (HBsAb) [7] defined by serum levels ≥ 10 IU/L although a level below 10 IU/L does not necessarily indicates loss of immunity [8] .
In Senegal, one of the most endemic countries for HBV in the world, the HBV vaccine has been introduced in 1999 and included in the No positive cases of HBsAg were noted in children over 10 years, but the sample size in that age group was small (n = 61). There was no significant difference in the prevalence of HBsAg by age and sex (1.4% versus 0.8%, p = 0.55).
Seroprevalence of HBcAb (HBcAb):
Out of 295 children, HBcAb could be tested in 267 and 12 (4.5%, 95% CI = 2.3-7.7)) were positive for this marker ( Table 1 However, no significant difference was found between these 2 studies (p = 0.139). Compared with national studies, our overall HBsAg carrier rate was lower than those in 930 children born from HIV-seropositive mothers (3.0%) [13] and 462 babies including 88 born to 80 HBsAg (+) mothers (HBsAg (+) (17%) than to HBsAg (-) (4%) women [14] . Moreover compared with international studies, the HBsAg prevalence observed in our study (1.1%) was lower than those found in Nigerian children aged 2 months to 15 years (13.9%) [15] , healthy Indonesian children (3.1%) [16] and HIV-infected children in Swaziland (1.4%) [17] . The discrepancy observed with other African countries is likely associated with several factors: a modest decrease in the HBsAg prevalence among African women, from 13.8% in 1992 to 11.57% in 2012 [14, 18] and different vaccine coverage over the African continent. According to the 2015 WHO-Unicef immunization report the HBV 3 doses vaccine coverage has improved in Senegal and was estimated at 89% in Senegal [6] .
In our study we found that 77.3%, (95%CI 71.6-82.4) had isolated positive HBsAb suggesting a HBV vaccine coverage close to 80% in our study population. HBV vaccination or infection induces the production of HBsAb, an immunoglobulin able to neutralize HBsAg in case. Along with other effector immune functions, the protective HBsAb can block the spread of HBV in the body. HBsAb levels persist in the blood for a long time but gradually decrease with age.
Our study confirms this effect (Figure 2 ). Our results are close to those reported by other authors in Senegal showing that the rate of positive HBsAb was 61 % in hospitalized children aged between 3 month to 6 years (p=0.302) [12] . Our results are however lower than those found in other HBV endemic countries where HBV vaccine coverage rates among children range from 90 to 98%. [19, 20] . We also found that the seroprotective rate of HBsAb levels was higher in males (56.6%) as compared to females (55.1%) (p > 0.05) suggesting gendre-guided immunity responses. In contrast previous studies reported better protective levels of HBsAb in vaccinated children (70%) [21] and 84.2% [22] with higher levels in girls as compared to boys. Such discrepancy could be attributed to differences in the primary immune response to vaccination, the type of vaccines used, the quality of vaccine storage (broken cold chain for instance) age groups, nutritional status and socioeconomic factors or race factors [23].
In our study protective level of HBsAb decreased with age from 65% in children below 5 years to 15.3% in those above 10 years.
Similar findings were reported in Egypt and China where the protection rate was inversely correlated with age [24, 25] . A study conducted in Yemen assessed the hepatitis B vaccine coverage and immune response in children below ten years and reported a 45.2%
children with low levels of HBs (< 10 UI/L) despite a full course of 3 doses vaccine [26] . These results suggested a poor response to HBV immunization in African children [27] . Interestingly we did not find any occult hepatitis B in the children enrolled in our study. In a recent study conducted in China, a low rate of occult hepatitis B (1.26%) was observed in 1.192 community children [28] . Our study has some limitations: first the parents were not surveyed on the history of hepatitis B in the family. Second we were not able to assess the number of HBV vaccine doses that were administrated to the children. It has been previously demonstrated that 3 doses are the best method to get effective protection against HBV and is better than one single dose. Third, we did not collect the HIV and 
Conclusion
This study reports a low rate of HBV infection (  This study shows the need, on the one hand, to evaluate the seroprotection of subjects after taking the three doses in order to propose boosting immunity and on the other hand to make an evaluation of the quality of vaccines, the vaccine storage system and the their usage. 
